AbbVie vs Procter & Gamble: Revenue, Profit and Business Model
AbbVie reported $61.2B of revenue in FY2025 and $4.2B of net income. Procter & Gamble reported $87B of revenue in FY2026 and $16B of net income.
Latest financial snapshot
AbbVie
- Latest revenue
- $61.2B (FY2025)
- Net income
- $4.2B
- Net margin
- 6.9%
- Revenue growth
- +10.1% a year, FY2016–FY2025
Procter & Gamble
- Latest revenue
- $87B (FY2026)
- Net income
- $16B
- Net margin
- 18.4%
- Revenue growth
- +3.3% a year, FY2017–FY2026
Financial summary
AbbVie
AbbVie reported $61.160 billion of FY2025 net revenue and $4.226 billion of net income. Skyrizi and Rinvoq generated $25.866 billion combined, while Humira declined to $4.540 billion after U.S. biosimilar entry. The 2020 Allergan acquisition added neuroscience and aesthetics revenue, and the 2024 ImmunoGen and Cerevel acquisitions added oncology and neuroscience assets.
Procter & Gamble
P&G's finances are defined by steady sales, high margins and large cash returns rather than fast growth. Net sales rose from $65.1 billion in fiscal 2017 to $87.0 billion in fiscal 2026. In fiscal 2026 diluted EPS was $6.62 (up 2%) and core EPS was $6.89 (up 1%), with core gross and operating margins slipping 40 and 70 basis points as costs rose. The company returned more than $15 billion to shareholders, about $10.2 billion in dividends and $5 billion in buybacks, and has raised its dividend for 70 consecutive years. For fiscal 2027 it guided to 1%-3% organic sales growth and core EPS of $6.89-$7.11.
Revenue and profit by year
AbbVie
| Year | Revenue | Net income | Margin | Growth | Source |
|---|---|---|---|---|---|
| FY2025 | $61.2B | $4.2B | 6.9% | +8.6% | Source |
| FY2024 | $56.3B | $4.3B | 7.6% | +3.7% | Source |
| FY2023 | $54.3B | $4.9B | 9.0% | -6.4% | Source |
| FY2022 | $58.1B | $11.8B | 20.4% | +3.3% | Source |
| FY2021 | $56.2B | $11.5B | 20.5% | +22.7% | Source |
| FY2020 | $45.8B | $4.6B | 10.1% | +37.7% | Source |
| FY2019 | $33.3B | $7.9B | 23.7% | +1.6% | Source |
| FY2018 | $32.8B | $5.7B | 17.4% | +16.1% | Source |
| FY2017 | $28.2B | $5.3B | 18.8% | +10.1% | Source |
| FY2016 | $25.6B | $6B | 23.2% | — | Source |
Procter & Gamble
| Year | Revenue | Net income | Margin | Growth | Source |
|---|---|---|---|---|---|
| FY2026 | $87B | $16B | 18.4% | +3.3% | Source |
| FY2025 | $84.3B | $16B | 19.0% | +0.3% | Source |
| FY2024 | $84B | $14.9B | 17.7% | +2.5% | Source |
| FY2023 | $82B | $14.7B | 17.9% | +2.3% | Source |
| FY2022 | $80.2B | $14.7B | 18.4% | +5.3% | Source |
| FY2021 | $76.1B | $14.3B | 18.8% | +7.3% | Source |
| FY2020 | $71B | $13B | 18.4% | +4.8% | Source |
| FY2019 | $67.7B | $3.9B | 5.8% | +1.3% | Source |
| FY2018 | $66.8B | $9.8B | 14.6% | +2.7% | Source |
| FY2017 | $65.1B | $15.3B | 23.6% | — | Source |
Where the revenue comes from
AbbVie
- Immunology Portfolio49.7%
FY2025 revenue was $30.406 billion, led by Skyrizi, Rinvoq, and Humira.
- Neuroscience Portfolio17.6%
FY2025 revenue was $10.767 billion, including Vraylar, Botox Therapeutic, Ubrelvy, and Qulipta.
- Oncology Portfolio10.9%
FY2025 revenue was $6.655 billion, including Imbruvica, Venclexta, and Elahere.
- Aesthetics Portfolio7.9%
FY2025 revenue was $4.860 billion, including Botox Cosmetic and Juvederm.
- Other Products and Revenue13.9%
The remaining FY2025 revenue came from eye care, other specialty products, and other revenue.
Procter & Gamble
- Fabric and Home Care
Largest segment
Laundry, dish care, air care, and household cleaning brands including Tide, Ariel, Dawn, Febreze, and Swiffer.
- Baby, Feminine and Family Care
Major segment
Pampers, Always, Bounty, Charmin, and related baby, feminine, and family-care products.
- Beauty
Major segment
Hair care, skin care, and prestige beauty brands including Head & Shoulders, Pantene, Olay, and SK-II.
- Health Care
Major segment
Oral care and personal health products such as Oral-B, Crest, Vicks, and Metamucil.
- Grooming
Focused segment
Gillette, Venus, Braun, and shaving-related products.
Business model and strategy
AbbVie
How it makes money
AbbVie earns revenue from global sales of prescription medicines and Allergan Aesthetics products. Its FY2025 portfolios were led by immunology at $30.406 billion, neuroscience at $10.767 billion, oncology at $6.655 billion, and aesthetics at $4.860 billion. The company funds internal research and supplements its pipeline through licensing and acquisitions.
Growth strategy
AbbVie is expanding approved uses and commercial reach for Skyrizi and Rinvoq while investing in oncology and neuroscience. ImmunoGen added Elahere and antibody-drug conjugate programs, Cerevel added clinical-stage neuroscience programs, and Allergan added Botox, Vraylar, migraine products, eye care, and aesthetics.
Competitive advantage
AbbVie's scale rests on its immunology portfolio, specialist commercial infrastructure, approved products across several therapeutic areas, and acquired oncology, neuroscience, and aesthetics assets. Those strengths are offset by patent-expiration, clinical-development, safety, reimbursement, and pricing risks described in its Form 10-K.
Procter & Gamble
How it makes money
P&G makes money by designing, manufacturing and marketing branded household and personal-care products that consumers buy every week, then selling them through retailers, club stores, pharmacies, distributors and e-commerce platforms. Revenue comes from five reportable segments: Fabric & Home Care (Tide, Ariel, Dawn, Downy, Febreze), the largest; Baby, Feminine & Family Care (Pampers, Always, Bounty, Charmin);
Growth strategy
P&G's integrated growth strategy has five parts: a portfolio focused on about ten daily-use categories, superiority across product, packaging, communication, retail execution and value, productivity savings to fund reinvestment, 'constructive disruption' of its own practices, and an agile, accountable organization.
Competitive advantage
P&G's edge is the combination of category leadership and scale. It concentrates on about ten daily-use categories where performance differences are visible to consumers (cleaning, absorbency, shaving, oral care), funds roughly $2 billion a year of R&D to keep those gaps, and uses its size to buy materials, media and logistics more cheaply than smaller rivals.
Questions about AbbVie vs Procter & Gamble
Which company has higher revenue — AbbVie Inc. or The Procter & Gamble Company?
AbbVie Inc. reported $61.2B (FY2025), while The Procter & Gamble Company reported $87.0B (FY2026). By last reported revenue, The Procter & Gamble Company is the larger business, with AbbVie Inc. reporting a smaller revenue base. Note: these are from different fiscal years and are not a direct like-for-like comparison.
What is the market cap of AbbVie Inc. vs The Procter & Gamble Company?
AbbVie Inc.'s market capitalisation stands at $465.8B, while The Procter & Gamble Company's is $340.0B. AbbVie Inc. carries the higher market valuation, reflecting investors' expectations of its future earnings power relative to The Procter & Gamble Company.
Which is more financially efficient — AbbVie Inc. or The Procter & Gamble Company?
AbbVie Inc. generates $1.07M / employee in revenue per employee, while The Procter & Gamble Company generates $798k / employee. AbbVie Inc. shows higher revenue efficiency per headcount, though this reflects business model differences — capital-light software companies routinely outperform labour-intensive manufacturers on this metric.
How do AbbVie Inc. and The Procter & Gamble Company make money?
AbbVie Inc. and The Procter & Gamble Company generate revenue in fundamentally different ways. AbbVie Inc.: AbbVie earns revenue from global sales of prescription medicines and Allergan Aesthetics products. The Procter & Gamble Company: P&G makes money by designing, manufacturing and marketing branded household and personal-care products that consumers buy every week, then selling them through retailers, club stores, pharmacies, distributors and e-commerce platforms.
Which company is valued higher relative to revenue — AbbVie Inc. or The Procter & Gamble Company?
On a price-to-sales (P/S) basis, AbbVie Inc. trades at 7.6x P/S and The Procter & Gamble Company at 3.9x P/S. AbbVie Inc. commands a higher revenue multiple, typically indicating that investors expect faster growth or higher future margins compared to The Procter & Gamble Company. A higher multiple is not inherently better — it may also signal that the stock is priced for perfection.
Is AbbVie Inc. bigger than The Procter & Gamble Company?
By last reported revenue, The Procter & Gamble Company ($87.0B (FY2026)) is the larger company compared to AbbVie Inc. ($61.2B (FY2025)). Revenue scale is one dimension of size — market capitalisation, employee count, and geographic reach are also relevant depending on the context.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the AbbVie vs Procter & Gamble overview